NCT00750230

Brief Summary

The purpose of this study was to evaluate the use of the dietary supplement Natural Eggshell Membrane (NEM) for the treatment of joint and connective tissue discomfort, pain, and flexibility.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2003

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2003

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2003

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2004

Completed
4.7 years until next milestone

First Submitted

Initial submission to the registry

September 8, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 10, 2008

Completed
Last Updated

September 7, 2023

Status Verified

February 1, 2016

Enrollment Period

2 months

First QC Date

September 8, 2008

Last Update Submit

September 5, 2023

Conditions

Keywords

arthritisosteoarthritisfibromyalgiaconnective tissue disorder

Outcome Measures

Primary Outcomes (1)

  • The primary outcome measure of this study was to evaluate the mean effectiveness of NEM® in relieving general pain associated with moderate joint & connective tissue disorders.

    7 & 30 days

Secondary Outcomes (3)

  • Additional outcome measures were to evaluate flexibility

    7 & 30 days

  • Secondary objectives of the study were to evaluate tolerability and any adverse reactions associated with supplementation with NEM®.

    7 & 30 days

  • To evaluate pain associated with the range of motion (ROM) evaluation.

    7 & 30 days

Study Arms (1)

NEM Treatment

EXPERIMENTAL

NEM, 500 mg, once daily, orally for 30 days.

Dietary Supplement: NEM

Interventions

NEMDIETARY_SUPPLEMENT

see Treatment Arm

Also known as: Natural Eggshell Membrane
NEM Treatment

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients seeking relief of mild to moderate pain due to joint or connective tissue (JCT)disorders.
  • subjects must have had persistent pain associated with a JCT disorder.
  • subjects were required to suspend all current pain relief medications.
  • Subjects that were currently taking analgesic medications were eligible to participate in the studies following a 14 day washout period for NSAIDs, a 7 day washout for narcotics, and a 90 day washout for injected steroids.
  • subjects currently taking glucosamine, chondroitin sulfate or MSM were only eligible after a 3-month washout period.

You may not qualify if:

  • Patients were excluded if they were currently receiving remission-inducing drugs such as methotrexate or immunosuppressive medications or had received them within the past 3 months.
  • body weight 250 pounds or greater.
  • a known allergy to eggs or egg products.
  • pregnant or breastfeeding women.
  • subjects previously enrolled in a study to evaluate pain relief within the past 6 months or currently involved in any other research study involving an investigational product (drug, device, or biologic) or a new application of an approved product, within 30 days of screening.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Robinson Family Clinic

Carthage, Missouri, 64836, United States

Location

Related Publications (1)

  • Ruff KJ, DeVore DP, Leu MD, Robinson MA. Eggshell membrane: a possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies. Clin Interv Aging. 2009;4:235-40. doi: 10.2147/cia.s5797. Epub 2009 Jun 9.

Related Links

MeSH Terms

Conditions

OsteoarthritisFibromyalgiaArthritisConnective Tissue Diseases

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal DiseasesRheumatic DiseasesMuscular DiseasesNeuromuscular DiseasesNervous System DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Kevin J Ruff, Ph.D., MBA

    ESM Technologies, LLC

    STUDY DIRECTOR
  • Mark A Robinson, D.C.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2008

First Posted

September 10, 2008

Study Start

October 1, 2003

Primary Completion

December 1, 2003

Study Completion

January 1, 2004

Last Updated

September 7, 2023

Record last verified: 2016-02

Data Sharing

IPD Sharing
Will not share

Locations